<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:22:18Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8700302" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8700302</identifier>
        <datestamp>2022-01-03</datestamp>
        <setSpec>lwwopen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Stroke</journal-id>
              <journal-id journal-id-type="iso-abbrev">Stroke</journal-id>
              <journal-id journal-id-type="publisher-id">STR</journal-id>
              <journal-title-group>
                <journal-title>Stroke</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0039-2499</issn>
              <issn pub-type="epub">1524-4628</issn>
              <publisher>
                <publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>
                <publisher-loc>Hagerstown, MD</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8700302</article-id>
              <article-id pub-id-type="pmcid">PMC8700302</article-id>
              <article-id pub-id-type="pmc-uid">8700302</article-id>
              <article-id pub-id-type="pmid">34847709</article-id>
              <article-id pub-id-type="pmid">34847709</article-id>
              <article-id pub-id-type="art-access-id">00007</article-id>
              <article-id pub-id-type="doi">10.1161/STROKEAHA.121.034866</article-id>
              <article-categories>
                <subj-group subj-group-type="hwp-journal-coll">
                  <subject>10029</subject>
                  <subject>10129</subject>
                  <subject>10176</subject>
                  <subject>10178</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Clinical Trial</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Effects of Cilostazol and Isosorbide Mononitrate on Cerebral Hemodynamics in the LACI-1 Randomized Controlled Trial</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Blair</surname>
                    <given-names>Gordon W.</given-names>
                  </name>
                  <degrees>MRCP</degrees>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <email>Gordon.Blair@ed.ac.uk</email>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Janssen</surname>
                    <given-names>Esther</given-names>
                  </name>
                  <degrees>MSc</degrees>
                  <xref rid="aff2" ref-type="aff">2</xref>
                  <email>janssen.esther1@gmail.com</email>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Stringer</surname>
                    <given-names>Michael S.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <email>m.stringer@ed.ac.uk</email>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Thrippleton</surname>
                    <given-names>Michael J.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <email>m.j.thrippleton@ed.ac.uk</email>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chappell</surname>
                    <given-names>Francesca</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <email>f.chappell@ed.ac.uk</email>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Shi</surname>
                    <given-names>Yulu</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <email>shi.yulu@hotmail.com</email>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hamilton</surname>
                    <given-names>Iona</given-names>
                  </name>
                  <degrees>BSc</degrees>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <email>igerrish@exseed.ed.ac.uk</email>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Flaherty</surname>
                    <given-names>Katie</given-names>
                  </name>
                  <degrees>MSc</degrees>
                  <xref rid="aff3" ref-type="aff">3</xref>
                  <email>katie_robson1990@hotmail.com</email>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Appleton</surname>
                    <given-names>Jason P.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff3" ref-type="aff">3</xref>
                  <xref rid="aff4" ref-type="aff">4</xref>
                  <email>jasonappleton@nhs.net</email>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Doubal</surname>
                    <given-names>Fergus N.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <email>fergus.doubal@ed.ac.uk</email>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bath</surname>
                    <given-names>Philip M.</given-names>
                  </name>
                  <degrees>DSc</degrees>
                  <xref rid="aff3" ref-type="aff">3</xref>
                  <xref rid="aff5" ref-type="aff">5</xref>
                  <email>philip.bath@nottingham.ac.uk</email>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Wardlaw</surname>
                    <given-names>Joanna M.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <aff id="aff1">Brain Research Imaging Centre, Centre for Clinical Brain Sciences, UK Dementia Institute Centre at the University of Edinburgh, United Kingdom (G.W.B., M.S.S., M.J.T., F.C., Y.S., I.H., F.N.D., J.M.W.).</aff>
                <aff id="aff2">Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Donders Centre for Medical Neuroscience, Radboud University Medical Center, Nijmegen, the Netherlands (E.J.).</aff>
                <aff id="aff3">Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (K.F., J.P.A., P.M.B.).</aff>
                <aff id="aff4">Stroke, University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Mindelsohn Way, United Kingdom (J.P.A.).</aff>
                <aff id="aff5">Stroke, Queenâ€™s Medical Centre Campus, Nottingham University Hospitals NHS Trust, United Kingdom (P.M.B.).</aff>
              </contrib-group>
              <author-notes>
                <corresp id="c1">Correspondence to: Joanna M. Wardlaw, MD, UK Dementia Institute Centre at the University of Edinburgh, Edinburgh EH16 4SB, United Kingdom. Email <email xlink:href="joanna.wardlaw@ed.ac.uk">joanna.wardlaw@ed.ac.uk</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>01</day>
                <month>12</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>1</month>
                <year>2022</year>
              </pub-date>
              <volume>53</volume>
              <issue>1</issue>
              <fpage>29</fpage>
              <lpage>33</lpage>
              <history>
                <date date-type="received">
                  <day>23</day>
                  <month>3</month>
                  <year>2021</year>
                </date>
                <date date-type="rev-recd">
                  <day>6</day>
                  <month>7</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>2</day>
                  <month>8</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Â© 2021 The Authors.</copyright-statement>
                <copyright-year>2021</copyright-year>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p><italic toggle="yes">Stroke</italic> is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.</license-p>
                </license>
              </permissions>
              <self-uri xlink:href="str-53-029.pdf"/>
              <abstract abstract-type="toc">
                <p>Supplemental Digital Content is available in the text.</p>
              </abstract>
              <abstract>
                <title>Background and Purpose:</title>
                <p>Cerebral small vessel diseaseâ€”a major cause of stroke and dementiaâ€”is associated with cerebrovascular dysfunction. We investigated whether short-term isosorbide mononitrate (ISMN) and cilostazol, alone or in combination, improved magnetic resonance imagingâ€“measured cerebrovascular function in patients with lacunar ischemic stroke.</p>
                <sec>
                  <title>Methods:</title>
                  <p>Participants were randomized to ISMN alone, cilostazol alone, both ISMN and cilostazol, or no medication. Participants underwent structural, cerebrovascular reactivity (to 6% carbon dioxide) and phase-contrast pulsatility magnetic resonance imaging at baseline and after 8 weeks of medication.</p>
                </sec>
                <sec>
                  <title>Results:</title>
                  <p>Of 27 participants (mean age, 68Â±7.7; 44% female), 22 completed cerebrovascular reactivity and pulsatility imaging with complete datasets. White matter cerebrovascular reactivity increased in the ISMN (Î²=0.021%/mm Hg [95% CI, 0.003â€“0.040]) and cilostazol (Î²=0.035%/mm Hg [95% CI, 0.014â€“0.056]) monotherapy groups and in those taking any versus no medication (Î²=0.021%/mm Hg [95% CI, 0.005â€“0.037]).</p>
                </sec>
                <sec>
                  <title>Conclusions:</title>
                  <p>While limited by small sample size, we demonstrate that measuring cerebrovascular function with magnetic resonance imaging is feasible in clinical trials and that ISMN and cilostazol may improve cerebrovascular function.</p>
                </sec>
                <sec>
                  <title>Registration:</title>
                  <p>URL: <ext-link xlink:href="https://www.clinicaltrials.gov" ext-link-type="uri">https://www.clinicaltrials.gov</ext-link>; Unique identifier: NCT02481323. URL: <ext-link xlink:href="www.isrctn.com" ext-link-type="uri">www.isrctn.com</ext-link>; Unique identifier: ISRCTN12580546. URL: <ext-link xlink:href="www.clinicaltrialsregister.eu" ext-link-type="uri">www.clinicaltrialsregister.eu</ext-link>; Unique identifier: EudraCT 2015-001953-33.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>cerebral small vessel diseases</kwd>
                <kwd>cilostazol</kwd>
                <kwd>cognitive dysfunction</kwd>
                <kwd>ischemic stroke</kwd>
                <kwd>magnetic resonance imaging</kwd>
              </kwd-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>OPEN-ACCESS</meta-name>
                  <meta-value>TRUE</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>SDC</meta-name>
                  <meta-value>T</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <p>Cerebral small vessel disease (SVD) is a major cause of stroke and dementia. No specific treatment exists to stop disease progression.<sup><xref rid="R1" ref-type="bibr">1</xref></sup></p>
            <p>SVD is associated with reduced cerebrovascular reactivity (CVR<sup><xref rid="R2" ref-type="bibr">2</xref></sup>; the ability of blood vessels to increase blood flow), more pulsatile blood flow, and impaired cerebrospinal fluid (CSF) dynamics.<sup><xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R3" ref-type="bibr">3</xref></sup></p>
            <p>Isosorbide mononitrate (ISMN) and cilostazol have pharmacological effects that could improve these cerebrovascular dysfunctions.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> Cilostazol can reduce stroke recurrence<sup><xref rid="R4" ref-type="bibr">4</xref></sup> and may reduce cognitive impairment.<sup><xref rid="R5" ref-type="bibr">5</xref></sup> Glyceryl trinitrateâ€”a shorter-acting nitrate than ISMNâ€”improved cognitive scores in some patients treated early after ischemic stroke.<sup><xref rid="R6" ref-type="bibr">6</xref></sup></p>
            <p>We measured CVR, cerebral blood flow, and CSF dynamics in patients with lacunar stroke randomly assigned to receive ISMN or cilostazol monotherapy, combination therapy, or avoid these medications in the LACI-1 trial (LACunar Intervention-1).<sup><xref rid="R7" ref-type="bibr">7</xref></sup></p>
            <sec sec-type="methods">
              <title>Methods</title>
              <sec sec-type="data-availability">
                <title>Data Availability Statement</title>
                <p>Access requests can be submitted to the corresponding author.</p>
              </sec>
              <sec>
                <title>Participants and Assessments</title>
                <p>This study was a substudy of the main LACI-1 trial. LACI- 1 was a phase IIa, partial factorial, prospective randomized open-label blinded end point trial. Our methods are published.<sup><xref rid="R7" ref-type="bibr">7</xref></sup> We recruited patients with nondisabling lacunar ischemic stroke.</p>
                <p>All participants were scanned at randomization and at week 8 in the cilostazol monotherapy, ISMN monotherapy, and ISMN and cilostazol groups and week 3 in the no-medication group (after which this group commenced cilostazol and ISMN to test the alternative order of starting dual therapy). Medication compliance, side effects, and blood pressure (BP) were also assessed at each visit.</p>
                <p>All participants provided written informed consent. Ethical approval was obtained from the Scotland-A Research Ethics Committee (Ref: 15/SS/0154).</p>
              </sec>
              <sec>
                <title>Intervention</title>
                <p>Participants were randomized to ISMN monotherapy, cilostazol monotherapy, combination ISMN, and cilostazol or no medication.<sup><xref rid="R7" ref-type="bibr">7</xref></sup> Dose was titrated to ISMN 25 mg BID and cilostazol 100 mg BID.<sup><xref rid="R7" ref-type="bibr">7</xref></sup> Medication was taken for 8 weeks. Participants were masked to treatment allocation, and investigators assessing outcomes including all image analysis were blinded to treatment allocation.<sup><xref rid="R7" ref-type="bibr">7</xref></sup></p>
              </sec>
              <sec>
                <title>Imaging</title>
                <p>We performed brain scanning using a 1.5T GE MRI scanner (SignaHDxt; General Electric, Milwaukee, WI). Structural sequences included T1-weighted, T2-weighted, fluid attenuated inversion recovery, and gradient recalled echo.</p>
              </sec>
              <sec>
                <title>CVR Acquisition</title>
                <p>During a 12-minute blood oxygen levelâ€“dependent magnetic resonance imaging (MRI) scan, participants alternated between breathing medical air and 6% carbon dioxide (CO<sub>2</sub>) in air, as is published previously.<sup><xref rid="R8" ref-type="bibr">8</xref></sup></p>
              </sec>
              <sec>
                <title>Pulsatility Acquisition</title>
                <p>Our pulsatility method is published previously.<sup><xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R3" ref-type="bibr">3</xref></sup> We used a 2-dimensional cine phase-contrast sequence to measure flow in the internal carotid and vertebral arteries, superior sagittal, straight, and transverse venous sinuses, and foramen magnum and aqueduct CSF flow.</p>
              </sec>
              <sec>
                <title>Image Analysis</title>
                <p>We performed CVR analysis by regressing blood oxygen levelâ€“dependent signal against end-tidal CO<sub>2</sub>, with CVR expressed as %blood oxygen levelâ€“dependent signal change/mmâ€‰Hg change in end-tidal CO<sub>2</sub> as published previously.<sup><xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref></sup> We extracted regional measurements of CVR in identical regions of the same anatomic structures at the two time points. Image analysis was performed by investigators blinded to treatment allocation.</p>
                <p>Structural and pulsatility analysis methods are pulished.<sup><xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R3" ref-type="bibr">3</xref></sup> Pulsatility index (PI) was calculated as (Flow<sub>maximum</sub>âˆ’Flow<sub>minimum</sub>)/Flow<sub>mean</sub>.</p>
              </sec>
              <sec>
                <title>Statistical Analysis</title>
                <p>We used R, version 1.0.143, for statistical analyses. To examine the effect of treatment, 2 separate analyses were done. First, an intention-to-treat analysis (main article) and second, a per-protocol analysis (<ext-link xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.121.034866" ext-link-type="uri">Supplemental Material</ext-link>) where participants who had stopped taking medication at the time of the follow-up scan were excluded from the treatment groups and analyzed as being in the no-medication group. We used multiple linear regression to assess the effect of treatment groups and being on any versus no medication on changes in white matter (WM) and gray matter CVR, PI, and CSF flow adjusting for age because this is suggested to affect CVR. This analysis was repeated and adjusted for systolic BP in place of age to examine the confounding effect of BP. To assure normality of the residuals and assess heteroscedasticity, we examined QQ plots, histograms of residuals, and plots of residual versus fitted values to examine.</p>
                <p>This analysis was repeated and adjusted for systolic BP in place of age to examine the confounding effect of BP. Additional analyses were also performed controlling for systolic BP change in place of age between baseline and follow-up.</p>
              </sec>
            </sec>
            <sec sec-type="results">
              <title>Results</title>
              <p>Twenty-seven of the 28 participants recruited to LACI-1 consented to the MRI substudy. Full CVR data sets were obtained in 23 participants and full pulsatility data sets in 24 (<ext-link xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.121.034866" ext-link-type="uri">Supplemental Material</ext-link>). The Figure shows the CONSORT flowchart.</p>
              <fig position="float" id="F1">
                <label>Figure.</label>
                <caption>
                  <p><bold>Change in cerebrovascular reactivity (CVR) by treatment group and any vs no medication.</bold> GM indicates gray matter; ISMN, isosorbide mononitrate; and WM, white matter.</p>
                </caption>
                <graphic xlink:href="str-53-029-g001" position="float"/>
              </fig>
              <p>The mean age of included participants was 68Â±7.7 years (range, 53â€“83 years), Table <xref rid="T1" ref-type="table">1</xref>.</p>
              <table-wrap position="float" id="T1">
                <label>Table 1.</label>
                <caption>
                  <p>Patient Characteristics</p>
                </caption>
                <graphic xlink:href="str-53-029-g002" position="float"/>
              </table-wrap>
              <sec>
                <title>CVR Change After Treatment</title>
                <p>WM CVR increased with ISMN and cilostazol monotherapy (both <italic toggle="yes">P</italic>&lt;0.05) and in participants taking any versus no trial drug (<italic toggle="yes">P</italic>&lt;0.05) but not combination therapy (Table <xref rid="T2" ref-type="table">2</xref>).</p>
                <table-wrap position="float" id="T2">
                  <label>Table 2.</label>
                  <caption>
                    <p>Associations Between Change in White Matter CVR, Intracranial Pulsatility, and Treatment</p>
                  </caption>
                  <graphic xlink:href="str-53-029-g003" position="float"/>
                </table-wrap>
                <p>There was no increase in gray matter CVR.</p>
              </sec>
              <sec>
                <title>Pulsatility Change After Treatment</title>
                <p>Superior sagittal sinus PI increased with cilostazol alone. Vertebral artery PI decreased with ISMN alone (Table <xref rid="T2" ref-type="table">2</xref>). CSF pulsatility did not change.</p>
              </sec>
            </sec>
            <sec sec-type="discussion">
              <title>Discussion</title>
              <p>Over an 8-week period, treatment with ISMN or cilostazol alone, or any drug versus no drug, increased WM but not gray matter CVR. Effects on pulsatility varied: ISMN decreased PI in the vertebral arteries; however, cilostazol increased superior sagittal sinus PI, which could be secondary to cilostazol increasing heart rate.<sup><xref rid="R7" ref-type="bibr">7</xref></sup> No changes in CSF flow dynamics were detected. Combination therapy did not have the effect of monotherapy although CVR in WM increased in participants taking any versus no medication, which includes those allocated dual therapy. Small numbers in each treatment group and participants finding it difficult to reach maximum dose of both drugs in combination means this is more likely sample size related and the true difference between effects of monotherapy versus combination remains undetermined.</p>
              <p>Prior studies have measured medication effects on resting cerebral blood flow in similar patient populations. The DANTE study (Discontinuation of Antihypertensives in the Elderly) showed no change in MRI-measured cerebral blood flow after antihypertensive medication withdrawal, compared with continuing antihypertensives.<sup><xref rid="R9" ref-type="bibr">9</xref></sup> The PRESERVE trial (Prevention of Serious Adverse Events Following Angiography) showed no change in MRI-measured cerebral blood flow with more versus less intensive BP lowering in patients with stroke-related moderate-to-severe SVD.<sup><xref rid="R10" ref-type="bibr">10</xref></sup> Others have demonstrated pravastatin, atorvastatin, perindopril, and vinpocetine all increase transcranial Doppler-measured vasoreactivity.<sup><xref rid="R11" ref-type="bibr">11</xref>â€“<xref rid="R15" ref-type="bibr">15</xref></sup> The changes in CVR we demonstrated were independent of any change in systolic BP induced by medication, adding further evidence that changes in blood flow and vascular function in older individuals with SVD have a complex relationship with BP. We have previously demonstrated stronger associations of WM than gray matter CVR with SVD.<sup><xref rid="R2" ref-type="bibr">2</xref></sup> WM may be differentially more impaired in SVD and thus more amenable to a detectable pharmacological improvement.</p>
              <p>Lack of improvement in PI could reflect that modification of vascular stiffening requires longer treatment. Cilostazol has previously been shown to decrease PI after 90 days in patients with lacunar infarction.<sup><xref rid="R16" ref-type="bibr">16</xref></sup></p>
              <sec>
                <title>Limitations</title>
                <p>The sample is small. However, a primary aim of LACI-1 was to establish feasibility of the drug regimen to inform a larger trial (LACI-2; ISRCTN14911850) and secondarily to gather efficacy and safety data.<sup><xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R17" ref-type="bibr">17</xref></sup></p>
                <p>The randomization was imperfect, as in the overall main trial,<sup><xref rid="R7" ref-type="bibr">7</xref></sup> with the cilostazol-only group being older.</p>
              </sec>
              <sec sec-type="conclusions">
                <title>Conclusions</title>
                <p>We demonstrated feasibility of cerebrovascular function MRI in a clinical trial of lacunar ischemic stroke and SVD and detected changes in CVR and pulsatility that support the positive modification of cerebrovascular function by existing medications. Larger studies over longer time periods will assess whether these improvements translate into clinical benefits.</p>
              </sec>
            </sec>
            <sec>
              <title>Article Information</title>
              <sec>
                <title>Acknowledgments</title>
                <p>We thank the participants and members of the trial committees.</p>
              </sec>
              <sec>
                <title>Sources of Funding</title>
                <p>Alzheimerâ€™s Society Ref: 252 (AS-PG-14-033). European Union Horizon 2020 project No. 666881, SVDs@Target (G.W. Blair Dr Stringer); Stroke Association Princess Margaret Research Development Fellowship (G.W. Blair); Stroke Association Garfield Weston Foundation Senior Clinical Lectureship (F.N. Doubal); National Health Service Research Scotland (F.N. Doubal); China Scholarship Council/University of Edinburgh (Dr Shi); National Health Service Lothian Research &amp; Development Office (Dr Thrippleton); Row Fogo Charitable Trust; Scottish Funding Council via Scottish Imaging Network, A Platform for Scientific Excellence Collaboration; Fondation Leducq (ref. 16CVD05); Edinburgh and Lothians Health Foundation; National Institute for Health Research (NIHR) Health Technology Assessment (HTA) TARDIS Trial (Dr Appleton and P.M. Bath); British Heart Foundation RIGHT-2 Trial (Dr Appleton and P.M. Bath); NIHR HTA TICH-2 trial (Tranexamic Acid for Hyperacute Primary Intracerebral Haemorrhage; K. Flaherty). P.M. Bath is Stroke Association Professor of Stroke Medicine and Emeritus NIHR Senior Investigator. UK Dementia Research Institute Centre at the University of Edinburgh (funded by the Medical Research Council, Alzheimerâ€™s Society and Alzheimerâ€™s Research UK; Dr Wardlaw).</p>
              </sec>
              <sec sec-type="COI-Statement">
                <title>Disclosures</title>
                <p>P.M. Bath is on the advisory boards of Sanofi, Nestle, DiaMedica, Moleac, Phagenesis, and ReNeuron. The other authors report no conflicts.</p>
              </sec>
              <sec>
                <title>Supplemental Material</title>
                <p>LACI-1 Trial Inclusion and Exclusion Criteria</p>
                <p>Supplemental Methods</p>
                <p>CONSORT Flowcharts</p>
                <p>Expanded Participant Characteristics Table</p>
                <p>Expanded Intention-to-Treat Results Table</p>
                <p>Per-Protocol Analyses</p>
                <p>Summary Table</p>
                <p>Expanded Acknowledgments</p>
                <p>CONSORT Checklist</p>
              </sec>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material id="SD1" position="float" content-type="local-data">
                <media id="s1" content-type="document" xlink:href="str-53-029-s001.pdf" position="anchor"/>
                <media id="s2" content-type="document" xlink:href="str-53-029-s002.pdf" position="anchor"/>
                <media id="s3" content-type="document" xlink:href="str-53-029-s003.pdf" position="anchor"/>
                <media id="s4" content-type="document" xlink:href="str-53-029-s004.pdf" position="anchor"/>
                <media id="s5" content-type="document" xlink:href="str-53-029-s005.pdf" position="anchor"/>
                <media id="s6" content-type="document" xlink:href="str-53-029-s006.pdf" position="anchor"/>
                <media id="s7" content-type="document" xlink:href="str-53-029-s007.pdf" position="anchor"/>
                <media id="s8" content-type="document" xlink:href="str-53-029-s008.pdf" position="anchor"/>
                <media id="s9" content-type="document" xlink:href="str-53-029-s009.pdf" position="anchor"/>
                <media id="s10" content-type="document" xlink:href="str-53-029-s010.pdf" position="anchor"/>
                <media id="s11" content-type="document" xlink:href="str-53-029-s011.pdf" position="anchor"/>
                <media id="s12" content-type="document" xlink:href="str-53-029-s012.pdf" position="anchor"/>
                <media id="s13" content-type="document" xlink:href="str-53-029-s013.pdf" position="anchor"/>
                <media id="s14" content-type="document" xlink:href="str-53-029-s014.jpg" position="anchor"/>
                <media id="s15" content-type="document" xlink:href="str-53-029-s015.pdf" position="anchor"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn fn-type="abbr">
                <p>
                  <def-list>
                    <title>Nonstandard Abbreviations and Acronyms</title>
                    <def-item>
                      <term>BP</term>
                      <def>
                        <p>blood pressure</p>
                      </def>
                    </def-item>
                    <def-item>
                      <term>CSF</term>
                      <def>
                        <p>cerebrospinal fluid</p>
                      </def>
                    </def-item>
                    <def-item>
                      <term>CVR</term>
                      <def>
                        <p>cerebrovascular reactivity</p>
                      </def>
                    </def-item>
                    <def-item>
                      <term>ISMN</term>
                      <def>
                        <p>isosorbide mononitrate</p>
                      </def>
                    </def-item>
                    <def-item>
                      <term>LACI-1</term>
                      <def>
                        <p>LACunar Intervention-1</p>
                      </def>
                    </def-item>
                    <def-item>
                      <term>MRI</term>
                      <def>
                        <p>magnetic resonance imaging</p>
                      </def>
                    </def-item>
                    <def-item>
                      <term>PI</term>
                      <def>
                        <p>pulsatility Index</p>
                      </def>
                    </def-item>
                    <def-item>
                      <term>SVD</term>
                      <def>
                        <p>small vessel disease</p>
                      </def>
                    </def-item>
                    <def-item>
                      <term>WM</term>
                      <def>
                        <p>white matter</p>
                      </def>
                    </def-item>
                  </def-list>
                </p>
              </fn>
            </fn-group>
            <fn-group>
              <fn fn-type="other" id="fn01">
                <p>This manuscript was sent to Stephen M. Davis, Guest Editor, for review by expert referees, editorial decision, and final disposition.</p>
              </fn>
              <fn fn-type="supplementary-material" id="fn02">
                <p>Supplemental Material is available at <ext-link xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.121.034866" ext-link-type="uri">https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.121.034866</ext-link>.</p>
              </fn>
              <fn fn-type="financial-disclosure" id="fn03">
                <p>For Sources of Funding and Disclosures, see page 33.</p>
              </fn>
            </fn-group>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>1.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bath</surname><given-names>PM</given-names></name><name><surname>Wardlaw</surname><given-names>JM</given-names></name></person-group>. <article-title>Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential interventions.</article-title><source>Int J Stroke</source>. <year>2015</year>;<volume>10</volume>:<fpage>469</fpage>â€“<lpage>478</lpage>. <comment>doi: 10.1111/ijs.12466</comment><pub-id pub-id-type="pmid">25727737</pub-id></mixed-citation>
              </ref>
              <ref id="R2">
                <label>2.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blair</surname><given-names>GW</given-names></name><name><surname>Thrippleton</surname><given-names>MJ</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Hamilton</surname><given-names>I</given-names></name><name><surname>Stringer</surname><given-names>M</given-names></name><name><surname>Chappell</surname><given-names>F</given-names></name><name><surname>Dickie</surname><given-names>DA</given-names></name><name><surname>Andrews</surname><given-names>P</given-names></name><name><surname>Marshall</surname><given-names>I</given-names></name><name><surname>Doubal</surname><given-names>FN</given-names></name><etal/></person-group>. <article-title>Intracranial hemodynamic relationships in patients with cerebral small vessel disease.</article-title><source>Neurology</source>. <year>2020</year>;<volume>94</volume>:<fpage>e2258</fpage>â€“<lpage>e2269</lpage>. <comment>doi: 10.1212/WNL.0000000000009483</comment><pub-id pub-id-type="pmid">32366534</pub-id></mixed-citation>
              </ref>
              <ref id="R3">
                <label>3.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Thrippleton</surname><given-names>MJ</given-names></name><name><surname>Blair</surname><given-names>GW</given-names></name><name><surname>Dickie</surname><given-names>DA</given-names></name><name><surname>Marshall</surname><given-names>I</given-names></name><name><surname>Hamilton</surname><given-names>I</given-names></name><name><surname>Doubal</surname><given-names>FN</given-names></name><name><surname>Chappell</surname><given-names>F</given-names></name><name><surname>Wardlaw</surname><given-names>JM</given-names></name></person-group>. <article-title>Small vessel disease is associated with altered cerebrovascular pulsatility but not resting cerebral blood flow.</article-title><source>J Cereb Blood Flow Metab</source>. <year>2020</year>;<volume>40</volume>:<fpage>85</fpage>â€“<lpage>99</lpage>. <comment>doi: 10.1177/0271678X18803956</comment><pub-id pub-id-type="pmid">30295558</pub-id></mixed-citation>
              </ref>
              <ref id="R4">
                <label>4.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McHutchison</surname><given-names>C</given-names></name><name><surname>Blair</surname><given-names>GW</given-names></name><name><surname>Appleton</surname><given-names>JP</given-names></name><name><surname>Chappell</surname><given-names>FM</given-names></name><name><surname>Doubal</surname><given-names>F</given-names></name><name><surname>Bath</surname><given-names>PM</given-names></name><name><surname>Wardlaw</surname><given-names>JM</given-names></name></person-group>. <article-title>Cilostazol for secondary prevention of stroke and cognitive decline: systematic review and meta-analysis.</article-title><source>Stroke</source>. <year>2020</year>;<volume>51</volume>:<fpage>2374</fpage>â€“<lpage>2385</lpage>. <comment>doi: 10.1161/STROKEAHA.120.029454</comment><pub-id pub-id-type="pmid">32646330</pub-id></mixed-citation>
              </ref>
              <ref id="R5">
                <label>5.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tai</surname><given-names>SY</given-names></name><name><surname>Chien</surname><given-names>CY</given-names></name><name><surname>Chang</surname><given-names>YH</given-names></name><name><surname>Yang</surname><given-names>YH</given-names></name></person-group>. <article-title>Cilostazol use is associated with reduced risk of dementia: a nationwide cohort study.</article-title><source>Neurotherapeutics</source>. <year>2017</year>;<volume>14</volume>:<fpage>784</fpage>â€“<lpage>791</lpage>. <comment>doi: 10.1007/s13311-017-0512-4</comment><pub-id pub-id-type="pmid">28194663</pub-id></mixed-citation>
              </ref>
              <ref id="R6">
                <label>6.</label>
                <mixed-citation publication-type="journal"><collab>ENOS Trial Investigators.</collab><article-title>Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised controlled trial.</article-title><source>Lancet</source>. <year>2015</year>;<volume>385</volume>:<fpage>617</fpage>â€“<lpage>628.</lpage><pub-id pub-id-type="pmid">25465108</pub-id></mixed-citation>
              </ref>
              <ref id="R7">
                <label>7.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blair</surname><given-names>GW</given-names></name><name><surname>Appleton</surname><given-names>JP</given-names></name><name><surname>Flaherty</surname><given-names>K</given-names></name><name><surname>Doubal</surname><given-names>F</given-names></name><name><surname>Sprigg</surname><given-names>N</given-names></name><name><surname>Dooley</surname><given-names>R</given-names></name><name><surname>Richardson</surname><given-names>C</given-names></name><name><surname>Hamilton</surname><given-names>I</given-names></name><name><surname>Law</surname><given-names>ZK</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Tolerability, safety and intermediary pharmacological effects of cilostazol and isosorbide mononitrate, alone and combined, in patients with lacunar ischaemic stroke: the LACunar Intervention-1 (LACI-1) trial, a randomised clinical trial.</article-title><source>EClinicalMedicine</source>. <year>2019</year>;<volume>11</volume>:<fpage>34</fpage>â€“<lpage>43</lpage>. <comment>doi: 10.1016/j.eclinm.2019.04.001</comment><pub-id pub-id-type="pmid">31317131</pub-id></mixed-citation>
              </ref>
              <ref id="R8">
                <label>8.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thrippleton</surname><given-names>MJ</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Blair</surname><given-names>G</given-names></name><name><surname>Hamilton</surname><given-names>I</given-names></name><name><surname>Waiter</surname><given-names>G</given-names></name><name><surname>Schwarzbauer</surname><given-names>C</given-names></name><name><surname>Pernet</surname><given-names>C</given-names></name><name><surname>Andrews</surname><given-names>PJ</given-names></name><name><surname>Marshall</surname><given-names>I</given-names></name><name><surname>Doubal</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Cerebrovascular reactivity measurement in cerebral small vessel disease: rationale and reproducibility of a protocol for MRI acquisition and image processing.</article-title><source>Int J Stroke</source>. <year>2018</year>;<volume>13</volume>:<fpage>195</fpage>â€“<lpage>206</lpage>. <comment>doi: 10.1177/1747493017730740</comment><pub-id pub-id-type="pmid">28933655</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <label>9.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foster-Dingley</surname><given-names>JC</given-names></name><name><surname>Moonen</surname><given-names>JE</given-names></name><name><surname>de Craen</surname><given-names>AJ</given-names></name><name><surname>de Ruijter</surname><given-names>W</given-names></name><name><surname>van der Mast</surname><given-names>RC</given-names></name><name><surname>van der Grond</surname><given-names>J</given-names></name></person-group>. <article-title>Blood pressure is not associated with cerebral blood flow in older persons.</article-title><source>Hypertension</source>. <year>2015</year>;<volume>66</volume>:<fpage>954</fpage>â€“<lpage>960</lpage>. <comment>doi: 10.1161/HYPERTENSIONAHA.115.05799</comment><pub-id pub-id-type="pmid">26351027</pub-id></mixed-citation>
              </ref>
              <ref id="R10">
                <label>10.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Croall</surname><given-names>ID</given-names></name><name><surname>Tozer</surname><given-names>DJ</given-names></name><name><surname>Moynihan</surname><given-names>B</given-names></name><name><surname>Khan</surname><given-names>U</given-names></name><name><surname>Oâ€™Brien</surname><given-names>JT</given-names></name><name><surname>Morris</surname><given-names>RG</given-names></name><name><surname>Cambridge</surname><given-names>VC</given-names></name><name><surname>Barrick</surname><given-names>TR</given-names></name><name><surname>Blamire</surname><given-names>AM</given-names></name><name><surname>Ford</surname><given-names>GA</given-names></name><etal/></person-group>; <collab>PRESERVE Study Team.</collab><article-title>Effect of standard vs intensive blood pressure control on cerebral blood flow in small vessel disease: the PRESERVE randomized clinical trial.</article-title><source>JAMA Neurol</source>. <year>2018</year>;<volume>75</volume>:<fpage>720</fpage>â€“<lpage>727</lpage>. <comment>doi: 10.1001/jamaneurol.2017.5153</comment><pub-id pub-id-type="pmid">29507944</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <label>11.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walters</surname><given-names>M</given-names></name><name><surname>Muir</surname><given-names>S</given-names></name><name><surname>Shah</surname><given-names>I</given-names></name><name><surname>Lees</surname><given-names>K</given-names></name></person-group>. <article-title>Effect of perindopril on cerebral vasomotor reactivity in patients with lacunar infarction.</article-title><source>Stroke</source>. <year>2004</year>;<volume>35</volume>:<fpage>1899</fpage>â€“<lpage>1902</lpage>. <comment>doi: 10.1161/01.STR.0000131748.12553.ed</comment><pub-id pub-id-type="pmid">15166388</pub-id></mixed-citation>
              </ref>
              <ref id="R12">
                <label>12.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sterzer</surname><given-names>P</given-names></name><name><surname>Meintzschel</surname><given-names>F</given-names></name><name><surname>RÃ¶sler</surname><given-names>A</given-names></name><name><surname>Lanfermann</surname><given-names>H</given-names></name><name><surname>Steinmetz</surname><given-names>H</given-names></name><name><surname>Sitzer</surname><given-names>M</given-names></name></person-group>. <article-title>Pravastatin improves cerebral vasomotor reactivity in patients with subcortical small-vessel disease.</article-title><source>Stroke</source>. <year>2001</year>;<volume>32</volume>:<fpage>2817</fpage>â€“<lpage>2820</lpage>. <comment>doi: 10.1161/hs1201.099663</comment><pub-id pub-id-type="pmid">11739979</pub-id></mixed-citation>
              </ref>
              <ref id="R13">
                <label>13.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>JovanoviÄ‡</surname><given-names>ZB</given-names></name><name><surname>PavloviÄ‡</surname><given-names>AM</given-names></name><name><surname>PekmezoviÄ‡</surname><given-names>T</given-names></name><name><surname>MijajloviÄ‡</surname><given-names>M</given-names></name><name><surname>CovickoviÄ‡</surname><given-names>NS</given-names></name></person-group>. <article-title>Transcranial Doppler assessment of cerebral vasomotor reactivity in evaluating the effects of vinpocetine in cerebral small vessel disease: a pilot study.</article-title><source>Ideggyogy Sz</source>. <year>2013</year>;<volume>66</volume>:<fpage>263</fpage>â€“<lpage>268</lpage>.<pub-id pub-id-type="pmid">23971358</pub-id></mixed-citation>
              </ref>
              <ref id="R14">
                <label>14.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sander</surname><given-names>K</given-names></name><name><surname>Hof</surname><given-names>U</given-names></name><name><surname>Poppert</surname><given-names>H</given-names></name><name><surname>Conrad</surname><given-names>B</given-names></name><name><surname>Sander</surname><given-names>D</given-names></name></person-group>. <article-title>Improved cerebral vasoreactivity after statin administration in healthy adults.</article-title><source>J Neuroimaging</source>. <year>2005</year>;<volume>15</volume>:<fpage>266</fpage>â€“<lpage>270</lpage>. <comment>doi: 10.1177/1051228405277403</comment><pub-id pub-id-type="pmid">15951410</pub-id></mixed-citation>
              </ref>
              <ref id="R15">
                <label>15.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pretnar-Oblak</surname><given-names>J</given-names></name><name><surname>Sabovic</surname><given-names>M</given-names></name><name><surname>Sebestjen</surname><given-names>M</given-names></name><name><surname>Pogacnik</surname><given-names>T</given-names></name><name><surname>Zaletel</surname><given-names>M</given-names></name></person-group>. <article-title>Influence of atorvastatin treatment on L-arginine cerebrovascular reactivity and flow-mediated dilatation in patients with lacunar infarctions.</article-title><source>Stroke</source>. <year>2006</year>;<volume>37</volume>:<fpage>2540</fpage>â€“<lpage>2545</lpage>. <comment>doi: 10.1161/01.STR.0000239659.99112.fb</comment><pub-id pub-id-type="pmid">16931784</pub-id></mixed-citation>
              </ref>
              <ref id="R16">
                <label>16.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>SW</given-names></name><name><surname>Song</surname><given-names>TJ</given-names></name><name><surname>Bushnell</surname><given-names>CD</given-names></name><name><surname>Lee</surname><given-names>S-S</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>GS</given-names></name><name><surname>Kim</surname><given-names>O-J</given-names></name><name><surname>Koh</surname><given-names>I-S</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><etal/></person-group>. <article-title>Cilostazol decreases cerebral arterial pulsatility in patients with mild white matter hyperintensities: subgroup analysis from the ECLIPSE study.</article-title><source>Cerebrovasc Dis</source>. <year>2014</year>;<volume>38</volume>:<fpage>197</fpage>â€“<lpage>203</lpage>. <comment>doi: 10.1159/000365840</comment><pub-id pub-id-type="pmid">25300977</pub-id></mixed-citation>
              </ref>
              <ref id="R17">
                <label>17.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Appleton</surname><given-names>JP</given-names></name><name><surname>Blair</surname><given-names>GW</given-names></name><name><surname>Flaherty</surname><given-names>K</given-names></name><name><surname>Law</surname><given-names>ZK</given-names></name><name><surname>May</surname><given-names>J</given-names></name><name><surname>Woodhouse</surname><given-names>LJ</given-names></name><name><surname>Doubal</surname><given-names>F</given-names></name><name><surname>Sprigg</surname><given-names>N</given-names></name><name><surname>Bath</surname><given-names>PM</given-names></name><name><surname>Wardlaw</surname><given-names>JM</given-names></name></person-group>. <article-title>Effects of isosorbide mononitrate and/or cilostazol on hematological markers, platelet function, and hemodynamics in patients with Lacunar Ischaemic Stroke: safety data from the Lacunar Intervention-1 (LACI-1) trial.</article-title><source>Front Neurol</source>. <year>2019</year>;<volume>10</volume>:<fpage>723</fpage>. <comment>doi: 10.3389/fneur.2019.00723</comment><pub-id pub-id-type="pmid">31333572</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
